Understanding CYP2D6 interactions

被引：26

作者：

de Groot, Marcel J.

Wakenhut, Florian

Whitlock, Gavin

Hyland, Ruth

机构：

[1] Pharmacokinetics, Dynamics and Metabolism (PDM)

来源：

DRUG DISCOVERY TODAY | 2009年 / 14卷 / 19-20期

关键词：

DRUG-DRUG INTERACTIONS; CYTOCHROME-P450 INHIBITION DATA; SUBSTRATE-SPECIFICITY; PHARMACOPHORE MODEL; ACCESSION NUMBERS; CRYSTAL-STRUCTURE; P450; SUPERFAMILY; COMBINED PROTEIN; 2D6; PREDICTION;

D O I：

10.1016/j.drudis.2009.07.005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Owing to the polymorphic nature of CYP2D6, clinically significant issues can arise when drugs rely on that enzyme either for clearance, or metabolism to an active metabolite. Available screening methods to determine if the compound is likely to cause drug-drug interactions, or is likely to be a victim of inhibition of CYP2D6 by other compounds will be described. Computational models and examples will be given on strategies to design out the CYP2D6 liabilities for both heme-binding compounds and non-heme-binding compounds.

引用

页码：964 / 972

页数：9

共 50 条

[1] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
Nahid, N.
Kanumuri, S.
Sharma, A.
Wang, D.
Johnson, J.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
[2] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
Kiss, Adam Ferenc
Toth, Katalin
Juhasz, Cintia
Temesvari, Manna
Paulik, Jozsef
Hirka, Gabor
Monostory, Katalin
MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
[3] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
Abduljalil, K.
Frank, D.
Gaedigk, A.
Klaassen, T.
Tomalik-Scharte, D.
Jetter, A.
Jaehde, U.
Kirchheiner, J.
Fuhr, U.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
[4] Understanding CYP2D6 and Its Role in Tamoxifen Metabolism
Smith, Edith Caroline
ONCOLOGY NURSING FORUM, 2013, 40 (06) : 547 - 548
[5] Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6
Livezey, Mara R.
Briggs, Erran D.
Bolles, Amanda K.
Nagy, Leslie D.
Fujiwara, Rina
Furge, Laura Lowe
XENOBIOTICA, 2014, 44 (04) : 309 - 319
[6] Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR
Hersberger, M
Marti-Jaun, J
Rentsch, K
Hänseler, E
CLINICAL CHEMISTRY, 2000, 46 (08) : 1072 - 1077
[7] Interactions of amphetamine analogs with human liver CYP2D6
Wu, DF
Otton, SV
Inaba, T
Kalow, W
Sellers, EM
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (11) : 1605 - 1612
[8] Analysis of CYP2D6 substrate interactions by computational methods
Ito, Yuko
Kondo, Hiroki
Goldfarb, Peter S.
Lewis, David F. V.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2008, 26 (06): : 947 - 956
[9] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
Gressier, F.
Verstuyft, C.
Hardy, P.
Becquemont, L.
Corruble, E.
JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
[10] Pharmaceutical interaction - No clinically relevant interactions in Cyp2d6
不详
PSYCHOPHARMAKOTHERAPIE, 2007, 14 (04): : A12 - A13

← 1 2 3 4 5 →